Swedbank AB Has $5.13 Million Holdings in Savara Inc. $SVRA

Swedbank AB raised its position in shares of Savara Inc. (NASDAQ:SVRA) by 54.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 850,000 shares of the company’s stock after purchasing an additional 300,000 shares during the quarter. Swedbank AB owned approximately 0.42% of Savara worth $5,126,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. F m Investments LLC increased its position in Savara by 56.5% during the 4th quarter. F m Investments LLC now owns 678,813 shares of the company’s stock valued at $4,093,000 after purchasing an additional 245,100 shares during the period. Nan Fung Trinity HK Ltd. acquired a new stake in Savara during the 4th quarter valued at approximately $10,182,000. Rosalind Advisors Inc. increased its position in Savara by 50.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock valued at $14,280,000 after purchasing an additional 1,345,056 shares during the period. Vanguard Group Inc. grew its position in shares of Savara by 20.8% during the 4th quarter. Vanguard Group Inc. now owns 10,041,647 shares of the company’s stock worth $60,551,000 after buying an additional 1,728,453 shares during the period. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of Savara during the 2nd quarter worth approximately $33,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Stock Performance

Shares of SVRA stock opened at $5.14 on Wednesday. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -9.18 and a beta of 0.28. Savara Inc. has a 52 week low of $1.89 and a 52 week high of $7.01. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.17. The firm has a 50 day moving average of $5.29 and a 200-day moving average of $5.53.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, equities analysts forecast that Savara Inc. will post -0.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SVRA has been the subject of several recent analyst reports. Oppenheimer initiated coverage on shares of Savara in a research report on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective for the company. Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. HC Wainwright reaffirmed a “buy” rating on shares of Savara in a research report on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. Finally, William Blair set a $10.00 price objective on shares of Savara in a research report on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $9.13.

Savara Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.